Breaking News Instant updates and real-time market news.

CSRA

CSRA

$31.08

0.64 (2.10%)

, REGN

Regeneron

$480.43

14.41 (3.09%)

09:55
06/05/17
06/05
09:55
06/05/17
09:55

Early notable gainers among liquid option names on June 5th

Notable gainers among liquid option names this morning include CSRA (CSRA) $31.14 +0.70, Regeneron (REGN) $488.53 +8.08, Intercontinental Exchange (ICE) $61.20 +0.95, State Street (STT) $83.73 +1.09, and Activision Blizzard (ATVI) $60.42 +0.78.

CSRA

CSRA

$31.08

0.64 (2.10%)

REGN

Regeneron

$480.43

14.41 (3.09%)

ICE

IntercontinentalExchange

$60.65

0.33 (0.55%)

STT

State Street

$84.03

1.35 (1.63%)

ATVI

Activision Blizzard

$59.65

0.09 (0.15%)

  • 07

    Jun

CSRA CSRA
$31.08

0.64 (2.10%)

04/05/17
04/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Burlington Stores (BURL) initiated with an Outperform at William Blair. 2. Booz Allen (BAH) was initiated with an In Line while CSRA (CSRA) was initiated with an Outperform at Evercore ISI. 3. Guidance Software (GUID) initiated with an Overweight at Piper Jaffray. 4. Acacia Communications (ACIA) initiated with a Neutral at B. Riley. 5. Keysight Technologies (KEYS) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/17
COWN
03/06/17
DOWNGRADE
COWN
Market Perform
CSRA downgraded to Market Perform from Outperform at Cowen
Cowen analyst Gautam Khanna downgraded CSRA to Market Perform and lowered its price target to $32 from $35 citing lack of near-term catalysts, flattish FY18 adjusted/earnings, and sizable re-competes over the next year that reduce FY19+ visibility.
03/16/17
VERT
03/16/17
INITIATION
VERT
Hold
CSRA initiated with a Hold at Vertical Research
Vertical Research analyst Krishna Sinha started CSRA with a Hold rating.
04/04/17
EVER
04/04/17
INITIATION
Target $34
EVER
Outperform
CSRA initiated with an Outperform at Evercore ISI
Evercore ISI analyst Rayna Kumar initiated CSRA with an Overweight and a $34 price target citing industry leading EBITDA margins driven by exposure to high margin, fixed price contracts, a next generation IT focus, and financial discipline.
REGN Regeneron
$480.43

14.41 (3.09%)

05/05/17
LEER
05/05/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron price target raised to $493 from $448 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $493 from $448 following quarterly results, and given the strength of peer company multiples and greater conviction about long-term profitability. The analyst reiterates an Outperform rating on the shares.
05/23/17
JEFF
05/23/17
NO CHANGE
Target $418
JEFF
Hold
Regeneron approval expected, but positive, says Jefferies
Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.
05/05/17
ADAM
05/05/17
UPGRADE
Target $484
ADAM
Buy
Regeneron upgraded to Buy at Canaccord
As reported previously, Canaccord analyst John Newman upgraded Regeneron to Buy from Hold. The analyst cited the strong investor sentiment toward the Dupixent launch, which he believes will drive the shares higher into Q2 and Q3 earnings. He also believes there will be less focus on Eylea revenues, despite slowing growth. Newman raised his price target to $484 from $375 on Regeneron shares.
05/05/17
UBSW
05/05/17
NO CHANGE
Target $489
UBSW
Buy
Regeneron price target raised to $489 from $446 at UBS
UBS analyst Carter Gould raised his price target on Regeneron to $489 from $446 following Q1 results. The analyst lowered his Eylea U.S. sales estimates based on Q1 trends, but he saw positives in the Dupixent update, including strong demand in atopic dermatitis. Also, the company has seen positive proof-of-concept data in eosinophilic esophagitis, which he noted was not in Street models. Gould reiterated his Buy rating on Regeneron shares.
ICE IntercontinentalExchange
$60.65

0.33 (0.55%)

03/30/17
RBCM
03/30/17
INITIATION
RBCM
Sector Perform
IntercontinentalExchange resumed with a Sector Perform at RBC Capital
RBC Capital analyst Peter Lenardos resumed coverage on IntercontinentalExchange with a $60 price target saying shares are fairly valued.
09/23/16
RBCM
09/23/16
NO CHANGE
RBCM
CBOE 'likely in the cross-hairs' of bigger peers, says RBC Capital
RBC Capital analyst Andrew Bond said he thinks the strategic risk of a deal whereby CBOE (CBOE) buys Bats Global Markets (BATS), as it has been reported to be in talks to do, outweighs the potential reward. However, he also believe CBOE's relatively small size, limited regulatory risk, clean balance sheet, and strong organic growth make it an attractive target for its largest exchange peers, such as IntercontinentalExchange (ICE) and CME Group (CME). A combined CBOE/BATS would be more difficult to acquire, so if CBOE is to be acquired, "the time is now," added Bond.
08/04/16
UBSW
08/04/16
NO CHANGE
Target $314
UBSW
Buy
IntercontinentalExchange price target raised to $314 from $279 at UBS
UBS raised its price target on IntercontinentalExchange to $314 from $279 as they believe the company is clicking on all cylinders. The firm cited strong Market Data growth, share repurchases, and growth in non-transactional revenues. UBS reiterated its Buy rating on IntercontinentalExchange shares.
STT State Street
$84.03

1.35 (1.63%)

04/13/17
DBAB
04/13/17
NO CHANGE
DBAB
Deutsche recommends long BNY Mellon, short State Street pair trade
Ahead of earnings reports from the brokers, asset managers and exchanges, Deutsche Bank analyst Brian Bedell recommends a pair trade to go long BNY Mellon (BK) versus short State Street (STT), as he sees NY Mellon narrowly beating consensus while he expects State Street to post a slight miss and also predicts downward revisions to 2017. Bedell keeps a Buy rating on BNY Mellon and a Hold rating on State Street.
05/26/17
BOFA
05/26/17
INITIATION
Target $88
BOFA
Neutral
State Street reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Michael Carrier reinstated coverage on State Street with a Neutral and a $88 price target citing its lower growth outlook.
05/26/17
05/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Outperform at Cowen. 2. Sherwin-Williams (SHW) initiated with a Hold at Jefferies. 3. State Street (STT) reinstated with a Neutral at BofA/Merrill. 4. Zoetis (ZTS) initiated with a Buy at CL King. 5. BioDelivery Sciences (BDSI) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/17
UBSW
06/05/17
UPGRADE
Target $92
UBSW
Buy
State Street upgraded to Buy from Neutral at UBS
UBS analyst Brennan Hawken upgraded State Street to Buy and raised his price target for the shares to $92 from $86. The analyst believes investor concerns about increased competitive pressure has brought an attractive buying opportunity. After meeting with management, Hawken has greater confidence in the earnings outlook for the company's European business.
ATVI Activision Blizzard
$59.65

0.09 (0.15%)

05/12/17
PIPR
05/12/17
NO CHANGE
PIPR
April NPD video game software sales rose 9%, says Piper Jaffray
Piper Jaffray analyst Michael Olson notes April NPD video game software sales were up 9% year-over-year, helped by the launch of Nintendo's (NTDOY) Switch console Top titles for the month included Nintendo's The Legend of Zelda: Breadth of the Wild and Mario Kart 8, Olson tells investors in a research note. The April numbers are less material since Activision Blizzard (ATVI) and Electronic Arts (EA) recently announced guidance for the June quarter, the analyst adds. He keeps an Overweight rating on those two names along with Take-Two Interactive (TTWO).
05/05/17
WEDB
05/05/17
NO CHANGE
WEDB
Activision Blizzard price target raised to $62.50 from $53 at Wedbush
Wedbush analyst Michael Pachter raised his price target on Activision after the company reported stronger than expected Q1 results. The analyst thinks that the company's 2017 guidance is conservative and believes that its EPS could reach $3 by 2018. He keeps an Outperform rating on the stock.
05/05/17
PACS
05/05/17
NO CHANGE
PACS
Activision Blizzard guidance appears conservative, says Pacific Crest
Pacific Crest analysts Evan Wingren and Andy Hargreaves say that Activision Blizzard's implied guidance appears to be conservative. The analysts think that the company has multiple potential positive catalysts for the rest of 2017 and is poised to benefit from the proliferation of digital games. They keep a $60 price target and an Overweight rating on the shares.
05/05/17
OPCO
05/05/17
NO CHANGE
Target $60
OPCO
Outperform
Activision Blizzard price target raised to $60 from $53 at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz raised his price target for Activision Blizzard to $60 from $53 following quarterly results. The analyst believes the company has proven, and will be able to continue to execute on its strategy to drive player engagement and investments through high quality content. Uerkwitz also thinks Activision Blizzard has untapped revenue growth from eSports, advertising, and cross-platform applications of its IP assets. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$29.18

-0.46 (-1.55%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Aclaris Therapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Week of 7/28 Baker-Hughes…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

JAGX

Jaguar Animal Health

$0.66

-0.0175 (-2.58%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Jaguar Animal Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

CALM

Cal-Maine Foods

$38.05

0.55 (1.47%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Cal-Maine Foods participates in a conference call with Stephens »

Stephens hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

, IBM

IBM

$145.07

-0.29 (-0.20%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
RSA Security to hold a conference »

RSA Security Conference…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

IBM

IBM

$145.07

-0.29 (-0.20%)

CTL

CenturyLink

$23.60

0.74 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

03:35
07/28/17
07/28
03:35
07/28/17
03:35
General news
FX Action: USD-CAD steady after posting its biggest one-day gain »

FX Action: USD-CAD steady…

01:40
07/28/17
07/28
01:40
07/28/17
01:40
General news
FX Update: The Swiss franc tumbled for a four straight session »

FX Update: The Swiss…

TOO

Teekay Offshore Partners

$2.55

-0.03 (-1.16%)

20:27
07/27/17
07/27
20:27
07/27/17
20:27
Downgrade
Teekay Offshore Partners rating change at Raymond James »

Teekay Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Downgrade
QEP Resources rating change at JPMorgan »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

RDFN

Redfin

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Syndicate
Redfin 9.231M share IPO priced at $15.00 »

The deal range is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 28

    Jul

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

, CVX

Chevron

$106.11

0.99 (0.94%)

20:25
07/27/17
07/27
20:25
07/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

CVX

Chevron

$106.11

0.99 (0.94%)

MRK

Merck

$63.69

1.89 (3.06%)

ABBV

AbbVie

$71.73

-0.86 (-1.18%)

AAL

American Airlines

$50.00

-1.01 (-1.98%)

COL

Rockwell Collins

$109.02

-0.53 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 07

    Aug

  • 28

    Aug

  • 22

    Sep

TTPH

Tetraphase

$6.96

-0.92 (-11.68%)

20:22
07/27/17
07/27
20:22
07/27/17
20:22
Syndicate
Tetraphase 10M share Secondary priced at $6.50 »

Piper Jaffray, BMO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

BVN

Buenaventura

$12.45

0.1 (0.81%)

19:26
07/27/17
07/27
19:26
07/27/17
19:26
Earnings
Buenaventura reports Q2 EPS (2c), may not compare to consensus 26c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:02
07/27/17
07/27
19:02
07/27/17
19:02
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:01
07/27/17
07/27
19:01
07/27/17
19:01
Earnings
Basic Energy reports Q2 adjusted EPS (57c), consensus (55c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

GE

General Electric

$25.79

0.2 (0.78%)

18:55
07/27/17
07/27
18:55
07/27/17
18:55
Periodicals
Breaking Periodicals news story on General Electric »

Uber CEO shortlists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AIV

Aimco

$44.01

0.13 (0.30%)

18:53
07/27/17
07/27
18:53
07/27/17
18:53
Earnings
Aimco reports Q2 AFFO 51c vs 50c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

NOV

National Oilwell

$33.71

0.37 (1.11%)

18:43
07/27/17
07/27
18:43
07/27/17
18:43
Earnings
National Oilwell reports Q2 adjusted EPS (14c), consensus (15c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 29

    Aug

AIG

AIG

$65.17

-0.02 (-0.03%)

, IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

18:39
07/27/17
07/27
18:39
07/27/17
18:39
Periodicals
Senators worried over whether Icahn is pushing regulators on AIG, Reuters says »

U.S. Democratic Senators…

AIG

AIG

$65.17

-0.02 (-0.03%)

IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

PRU

Prudential

$112.74

0.55 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 03

    Aug

  • 27

    Sep

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

18:24
07/27/17
07/27
18:24
07/27/17
18:24
Earnings
Heritage Commerce reports Q2 EPS 19c, consensus 19c »

Reports Q2 NII $24.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.